MK-7762 is a novel oxazolidinone antituberculosis drug, structurally similar to linezolid. It demonstrated in vivo efficacy, lesion penetration and limited toxicity compared to linezolid. These properties suggest that it could be used in a broad regimen for the treatment of tuberculosis. The agent was discovered and developed to reduce toxicity in the treatment of tuberculosis. The study was published in Nature Medicine online on January 13, 2026 (doi:10.1038/s41591-025-04164-x).[1][2][3]